QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Q32 Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.79+0.27 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
31.5%+4852.4 pts over 5 years
Net margin
55.5%+4818.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | +155.9% | +81.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -56.6% | 125.1% | |
| Return on assets | – | -44.8% | 38.7% | |
| Current ratio | – | 9.69 | 4.85 | |
| Capex to revenue | – | 138.2% | 0.0% | |
| Diluted shares | – | 0M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Q32 Bio generated $343.35M from operations and spent $3.76M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$343.35M
Used
$3.76M
Capital expenditure$3.76M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin55.5%
×Asset turnover0.70×
×Equity multiplier3.23×
=Return on equity, FY2025125.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 55.5% | 0.70× | 3.23× | 125.1% |
| FY2023 | 808.0% | -0.05× | -0.88× | 34.3% |
| FY2022 | -156.0% | 0.01× | 11.30× | -25.7% |
| FY2021 | -281.9% | 0.14× | 1.30× | -52.4% |
| FY2020 | -4762.9% | 0.01× | 1.26× | -56.6% |
| FY2019 | -6237.5% | 0.01× | 1.25× | -45.7% |
| FY2018 | -1044.3% | 0.03× | 2.53× | -70.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$29.82M
- Cash generatingOperating cash flow above zero-$33.54M
- Return on assets improvedROA up on the prior year-101.4% → 32.3%
- Earnings backed by cashOperating cash flow above net income-$33.54M vs $29.82M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.97 → 4.85
- No dilutionShare count did not rise10M → 12M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.58